Published: 9 January 2023
Author(s): Shuzhen Bai, Chu Lin, Ruoyang Jiao, Xiaoling Cai, Suiyuan Hu, Fang Lv, Wenjia Yang, Xingyun Zhu, Linong Ji
Issue: March 2023
Section: Original article

Patients with type 2 diabetes (T2D) suffer from a higher risk of cardiovascular events and renal events, which are strongly associated with morality [1–3]. The novel anti-hyperglycemic agent, glucagon-like peptide 1 receptor agonist (GLP-1RA) has drawn a great deal of attention due to its potent efficacies in lowering glycemia, losing body weight, reducing blood pressure and more importantly contributing to favorable cardiorenal prognosis. Published cardiovascular outcome trials (CVOTs) have validated the substantial cardiovascular benefits of GLP-1RAs [4–8].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.